Related by context. All words. (Click for frequent words.) 71 HGS# 71 MGd 70 Xanafide 70 Phase Ib study 70 liposomal formulation 70 Aplidin 70 MAGE A3 ASCI 70 pharmacodynamic PD 69 CDK inhibitor 69 alvespimycin 69 fosbretabulin 69 VNP#M 69 forodesine 69 Cloretazine 69 PEG IFN 69 HuMax EGFr 69 CBLC# 69 ELACYT 68 pomalidomide 68 Omacetaxine 68 vidofludimus 68 Azedra 68 bendamustine 68 nucleotide analog 68 viral kinetics 68 receptor tyrosine kinase inhibitor 68 sorafenib Nexavar 68 mertansine 68 Traficet EN 68 relapsed MCL 68 oral prodrug 68 pertuzumab 68 phase Ib 68 XmAb# 68 neratinib 68 galiximab 67 Phase Ib II 67 elotuzumab 67 GLYX 67 pharmacokinetic PK study 67 ENMD # 67 relapsed MM 67 ara C 67 ganetespib 67 Panzem R NCD 67 non nucleoside 67 riociguat 67 ESBA# 67 PSMA ADC 67 HGS ETR2 67 alkylating agent 67 pharmacodynamic effects 67 Cloretazine ® 67 DermaVir Patch 67 Phase 1a clinical 67 Deforolimus 67 phase IIb clinical 67 mapatumumab 66 IMA# 66 ON #.Na 66 cariprazine 66 selective orally bioavailable 66 EOquin TM 66 Triapine R 66 HGS ETR1 66 BAL# [002] 66 GMX# 66 enzastaurin 66 Kahalalide F 66 YONDELIS 66 favorable pharmacokinetic profile 66 Quinamed 66 pharmacokinetic PK 66 bevacizumab Avastin R 66 ritonavir boosted 66 huN# DM1 66 AEG# 66 Symadex 66 eniluracil 66 Panzem NCD 66 evaluating tivozanib 66 PNP inhibitor 66 busulfan 66 Aflibercept 66 NS#/#A protease 66 cetuximab Erbitux R 66 OncoGel 66 tanespimycin 66 nab paclitaxel 66 Alocrest 66 indibulin 66 vascular disrupting agent 66 cytostatic 66 Phase #b/#a clinical 66 antiviral efficacy 66 antitumor effect 66 viral kinetic 66 PSN# [002] 66 dose cohort 65 EndoTAG TM -1 65 multicenter Phase II 65 anticancer activity 65 adecatumumab 65 lumiliximab 65 Pharmacokinetic 65 dose proportionality 65 Cloretazine R 65 antitumor activity 65 ruxolitinib 65 orally administered inhibitor 65 monoclonal antibody conjugated 65 nucleoside analog 65 Telintra 65 omega interferon 65 CA9 SCAN 65 OMNARIS HFA 65 Apoptone 65 INCB# [001] 65 sorafenib Nexavar ® 65 generation purine nucleoside 65 Lenocta 65 gemcitabine carboplatin 65 anti leukemic 65 axitinib 65 pharmacodynamic profile 65 preclinical efficacy 65 Bicifadine 65 corticosteroid dexamethasone 65 romidepsin 65 MP4OX 65 HQK 65 torezolid 65 bortezomib Velcade 65 Phase IIb III 65 chemotherapeutic drug 65 ONCONASE R 65 multicenter randomized placebo controlled 65 metastatic malignant 65 Altastaph 65 Carfilzomib 65 delafloxacin 65 solithromycin 65 trabectedin 65 idarubicin 65 proteasome inhibitor bortezomib 65 cediranib 65 PEGylated interferon 65 HuMax CD4 65 Vidaza azacitidine 65 kinase inhibition 65 GFT# 65 Leukine ® 65 trastuzumab DM1 T DM1 65 pharmacodynamics PD 65 docetaxel chemotherapy 65 ZD# [001] 65 crizotinib PF # 65 cilengitide 65 ATL/TV# 65 metaglidasen 65 standard chemotherapy regimen 65 epigenetic therapies 65 mitomycin 65 flavopiridol 65 BNC# 65 JAK inhibitor 65 oral ridaforolimus 65 Blinatumomab 65 randomized Phase IIb 65 liposomal doxorubicin 65 oral rivaroxaban 65 PRTX 65 phase IIa clinical 65 Phase Ib clinical 65 pharmacokinetic interactions 65 sulodexide 65 Tyrima 65 farletuzumab 65 Epratuzumab 65 phase IIa 65 CTAP# Capsules 65 ZOLINZA 65 Bezielle 64 OXi# 64 ChronVac C ® 64 teriflunomide 64 pharmacodynamic properties 64 Ophena TM 64 R#/MEM # 64 BrachySil TM 64 docetaxel Taxotere R 64 erlotinib Tarceva ® 64 xenograft models 64 Degarelix 64 lintuzumab 64 CD3 monoclonal antibody 64 antitumour activity 64 orally bioavailable 64 preclinically 64 CoFactor 64 DAVANAT 64 intratumoral 64 Tarceva TM 64 TLK# 64 SAR# [004] 64 tipranavir 64 recurrent glioblastoma multiforme 64 refractory chronic lymphocytic 64 elacytarabine 64 vorinostat 64 CYT# potent vascular disrupting 64 CANCIDAS 64 Dasatinib 64 clevidipine 64 Pharmacokinetics PK 64 Chemophase 64 antiangiogenic therapy 64 TRO# 64 orally dosed 64 pharmacokinetic PK profile 64 GAP #B# 64 Enzastaurin 64 Archexin 64 DACH platinum 64 AKT inhibitor 64 LCP AtorFen 64 AZILECT ® 64 intranasal formulation 64 sitaxsentan 64 Cloretazine R VNP#M 64 Darusentan 64 BRAF inhibitor 64 TBC# 64 dosing cohort 64 DCCR 64 neurologic progression 64 oral antiviral 64 CA4P 64 ceftazidime 64 PI3K inhibitor 64 Ampligen ® 64 pharmacokinetics PK 64 p# biomarker 64 Safinamide 64 trastuzumab emtansine T DM1 64 Randomized Double blind 64 docetaxel Taxotere ® 64 receptor inhibitor 64 OMP #M# 64 PHX# 64 CIMZIA TM 64 Darinaparsin 64 Xeloda ® 64 inecalcitol 64 bevacizumab Avastin ® 64 FOLFOX6 chemotherapy regimen 64 Nanobody 64 phase IIb trial 64 Azacitidine 64 AEGR 64 hA# 64 PDE4 inhibitor 64 fluoropyrimidine 64 Poly ICLC 64 virus HCV protease inhibitor 64 pioglitazone HCl 64 ADAGIO study 64 paclitaxel poliglumex 64 CCX# 64 pharmacokinetic parameters 64 Doxil ® 64 ribavirin RBV 64 Xelox 64 tubulin inhibitor 64 MERLIN TIMI 64 decitabine 64 relapsed multiple myeloma 64 Onconase 64 Annexin V 64 gemcitabine Gemzar ® 64 thymalfasin 64 investigational humanized monoclonal antibody 64 dexamethasone Decadron 64 IMC A# 64 bortezomib Velcade R 64 genotypic resistance 64 thalidomide Thalomid 64 dasatinib Sprycel 64 Phase #/#a 64 orally inhaled 64 doxorubicin docetaxel 64 FOLOTYN ® 64 rHuPH# 64 Tarvacin 64 CCX# B 64 budesonide foam 64 bactericidal activity 64 EGFR TKI 64 velafermin 64 dose escalation Phase 63 prucalopride 63 ongoing Phase 1b 63 BMS# 63 PRT# 63 TRV# [001] 63 mGluR5 NAM 63 demonstrated antitumor activity 63 papillary renal cell carcinoma 63 OncoVEX GM CSF 63 randomized blinded 63 BAY #-# 63 Teriflunomide 63 pegylated liposomal doxorubicin 63 granisetron 63 dose dexamethasone 63 Pegylated Liposomal Doxorubicin 63 aleglitazar 63 Phase 1b clinical trials 63 tumor necrosis 63 dose cohorts 63 TRAIL R2 63 Sym# 63 Phase #b/#a 63 huC# DM4 63 Pertuzumab 63 plasma kallikrein inhibitor 63 TELINTRA 63 GAMMAGARD 63 sunitinib malate 63 florbetaben 63 #I TM# 63 MYDICAR ® 63 rALLy clinical trial 63 ILLUMINATE 63 EDEMA3 trial 63 Omacetaxine mepesuccinate 63 oral picoplatin 63 octreotide implant 63 topoisomerase II inhibitor 63 TO AVOID PREGNANCY WHILE 63 humanized monoclonal 63 tipranavir r 63 CIMZIA ™ 63 NATRECOR ® 63 ARIKACE 63 nitazoxanide 63 microtubule inhibitor 63 Maximum Tolerated Dose MTD 63 Telatinib 63 MVA MUC1 IL2 63 Fludara ® 63 gemcitabine Gemzar 63 QTc prolongation 63 biodistribution 63 GRN# 63 isatoribine 63 sodium glucose cotransporter 63 Aptivus ® 63 RE LY ® 63 Vidaza ® 63 plasma pharmacokinetics 63 CYC# 63 Phase 1b trial 63 PXD# 63 immunomodulator 63 PDX pralatrexate 63 Dacogen decitabine 63 Curaxin CBLC# 63 ascending dose 63 Vaxfectin TM adjuvant 63 Pazopanib 63 intravenous cyclophosphamide 63 liposome formulation 63 trastuzumab Herceptin ® 63 antiangiogenic agents 63 intravenously administered 63 gefitinib Iressa 63 MYCAMINE 63 BARACLUDE R 63 pan HDAC inhibitor 63 Cloretazine VNP#M 63 pharmacologically active isomer 63 5alpha reductase 63 GRASPA ® 63 blinded randomized placebo controlled 63 secretory phospholipase A2 sPLA2 63 lenalidomide Revlimid R 63 leukemia AML 63 vinorelbine tartrate 63 Anavex #-# 63 Amplimexon 63 CYT# 63 Spiegelmer ® 63 trabedersen 63 polymerase inhibitor 63 OHR/AVR# 63 PegIFN RBV 63 Capesaris 63 surrogate endpoint 63 SNT MC# 63 inotropic 63 ispinesib administered 63 tiuxetan 63 VAPRISOL 63 zanolimumab 63 acyclovir Lauriad R 63 sargramostim 63 GRN#L 63 anti amnesic 63 Lp PLA 2 63 vascular disrupting agents 63 Acute Ischemic Stroke 63 OvaRex R 63 Lixivaptan 63 DCVax ® 63 depsipeptide 63 Fulvestrant 63 IAP inhibitor 63 ospemifene 63 maximally tolerated dose 63 PRIMO CABG 63 Phase IIb clinical trials 63 davunetide intranasal AL 63 systemic anaplastic large 63 paclitaxel Taxol 63 multicenter Phase 63 DepoVax 63 estramustine 63 HCD# [002] 63 selective androgen receptor modulator 63 Zybrestat 63 novel histone deacetylase 63 CIMZIA TM certolizumab pegol 63 PKC# 63 anticancer agent 63 Aclidinium 63 cetuximab Erbitux ® 63 dose escalation clinical 63 salmeterol fluticasone 63 mycophenolate mofetil 63 HER2 overexpression 63 AeroLEF TM 63 Tarvacin TM 63 TLR8 agonist 63 CRLX# 63 concurrent chemoradiation 63 DASISION 63 Vitaxin 63 Clolar ® 63 vemurafenib 63 OvaRex MAb 63 Azedra TM 63 antifolate 63 Vilazodone 63 temsirolimus Torisel ® 63 lanreotide 63 low dose cytarabine 63 Cleviprex TM clevidipine 63 posaconazole 63 DXL# 63 EOquin 62 Pemetrexed 62 Virulizin ® 62 palifosfamide 62 goserelin 62 amifostine 62 subcutaneous PRO 62 Ramoplanin 62 tolerability pharmacokinetics 62 epoetin alpha 62 radiation sensitizer 62 DDP# 62 OncoVEX 62 tipifarnib 62 alemtuzumab MS 62 Bortezomib 62 PROSTVAC TM 62 phase IIb 62 multicentre randomized 62 entinostat 62 Dapagliflozin 62 Annamycin 62 pharmacokinetic pharmacodynamic PK PD 62 p# inhibitor 62 Factor VIIa 62 INT# [002] 62 HSP# inhibitor 62 torezolid phosphate 62 immune modulating 62 epithelial tumors 62 bexarotene 62 epothilone 62 INTERCEPT platelets 62 PI3K/Akt pathway inhibitor 62 NXL# 62 tumorigenicity 62 HER2 antibody 62 cMET 62 dexpramipexole 62 anti CD3 62 UPLYSO 62 favorable tolerability 62 targeted antifolate 62 Luteinizing Hormone Releasing Hormone 62 eculizumab therapy 62 direct thrombin inhibitors 62 pharmacodynamic markers 62 CRMD# 62 Liposomal 62 selective modulator 62 ADVANCE PD 62 confirmatory clinical 62 Pharmacokinetic studies 62 IFN α 62 gemcitabine cisplatin 62 amprenavir 62 PANVAC VF 62 Ceflatonin 62 Hsp# Inhibitor 62 Pharmacokinetic PK 62 angiogenesis inhibitor 62 investigational HCV polymerase 62 Amrubicin 62 DAPT 62 analgesic efficacy 62 erythropoietic 62 histone deacetylase HDAC inhibitor 62 R baclofen 62 highly selective inhibitor 62 STRIDE PD 62 NP2 Enkephalin 62 MYDICAR 62 #F FDG PET 62 Elagolix 62 phase IIb study 62 protease inhibitor PI 62 Elvitegravir 62 Sapacitabine 62 Pralatrexate 62 fluvastatin 62 NPC 1C 62 NEUGENE 62 PROCHYMAL 62 APTIVUS r 62 YONDELIS R 62 dacetuzumab 62 LAB CGRP 62 cardiac troponin 62 q8h 62 zileuton 62 HCV SPRINT 62 chemotherapeutic regimen 62 ofatumumab HuMax CD# 62 inhibitor RG# 62 intradermal injection 62 TG# [003] 62 HCV replicon 62 GRNVAC1 62 HuLuc# 62 Glufosfamide 62 Temsirolimus 62 ARIKACE ™ 62 inhaled iloprost 62 interleukin IL -# 62 zoledronate 62 double blinded randomized 62 ZACTIMA 62 obatoclax 62 HDACi 62 taxane resistant 62 MabCampath 62 melphalan prednisone 62 Iloperidone 62 Phase 2a trial 62 Squalamine 62 Aurexis 62 SPRYCEL ® 62 ponatinib 62 lenalidomide dexamethasone 62 hyperphenylalaninemia HPA due 62 antiangiogenic activity 62 5 FU leucovorin 62 ularitide 62 pharmacokinetic equivalence 62 celgosivir 62 USL# 62 AST ALT 62 intravesical 62 trastuzumab Herceptin R 62 ancrod 62 PROSTASCINT R 62 Onrigin 62 vinca alkaloid 62 T#I [002] 62 trastuzumab DM1 62 PREVENT IV 62 Mycophenolate Mofetil 62 sapacitabine 62 Aplidin R 62 nadolol 62 histone deacetylase inhibitor 62 JAK inhibitors 62 HuMax CD# 62 Gleevec resistant 62 HCV protease inhibitors 62 AzaSite Plus 62 non nucleoside inhibitor 62 subcutaneously administered 62 ExTRACT TIMI 62 TMC# r 62 bortezomib Velcade ® 62 placebo controlled clinical 62 #beta estradiol 62 ALGRX 62 Neulasta ® 62 Interferon alpha 62 multi kinase inhibitor 62 Aurora Kinase 62 Voreloxin 62 synthase TS 62 CHARISMA trial 62 muscarinic 62 vapreotide acetate 62 retaspimycin 62 pramlintide metreleptin combination 62 phase 2a 62 anticancer compound 62 liver metastasis 62 hepatic fibrosis 62 effector function 62 radiation dosimetry 62 IL# PE#QQR 62 TREANDA 62 PEG SN# 62 factor Xa inhibitor 62 JVRS 62 selective antagonist 62 LHRH antagonists 62 boosted protease inhibitor 62 interferon alfa 2b 62 CINQUIL 62 alpha 2a 62 EKC Cide 62 pharmacodynamic parameters 62 immune modulatory 62 complete cytogenetic response 62 Alferon N 62 antitumor 62 PEGylated Fab fragment 62 vivo potency 62 intranasal delivery 62 CCR5 antagonist 62 TMC# [002] 62 triphendiol 62 Intravail R 62 Afatinib 62 Trofex 62 therapeutic monoclonal antibody 62 paclitaxel Taxol ® 62 corrected QT interval 62 Immunotherapeutic 62 including eniluracil ADH 62 registrational Phase 62 rFIXFc 62 Lenalidomide 62 safety tolerability pharmacokinetic 62 HER2 positive metastatic breast 62 Targretin 62 nanomolar 62 double blinded placebo 62 oblimersen 62 Valdoxan 62 denileukin diftitox 62 Subgroup analysis 62 TLR9 agonist 62 visilizumab 62 vitro cytotoxicity 62 Ozarelix 62 Pivotal Phase III 62 brivaracetam 62 abacavir Ziagen 62 Antiviral Activity 61 S/GSK# 61 BIBW 61 dosage regimens 61 randomized controlled Phase 61 haematologic 61 intermittent dosing 61 Thiovir 61 fosamprenavir 61 relapsed myeloma 61 phase Ib clinical 61 Insulin PH# 61 oral deforolimus 61 somatostatin analog 61 azacytidine 61 replicon 61 PPAR gamma agonist 61 tocilizumab 61 PTH analogue 61 SERCA2a 61 GSK# [001] 61 antithrombotic 61 liposomal amphotericin B 61 vascular disrupting 61 Anticalins R 61 masitinib 61 null responder 61 talabostat 61 proteasome inhibitor 61 CHAMPION PCI 61 cisplatin gemcitabine 61 Tipranavir 61 Vaprisol 61 SCH # 61 zafirlukast 61 radezolid 61 NRTI resistance 61 LUX Lung 61 oral FTY# 61 trial evaluating PRX# 61 targeting CD# 61 APTIVUS 61 regorafenib 61 RLY# 61 CD# monoclonal antibody 61 randomized multicenter Phase III 61 potent cytotoxic 61 plus DOXIL 61 assessing T DM1 61 plus prednisone prednisolone 61 Myocet 61 Janus Kinase 61 antitumoral 61 evaluating Actimmune 61 Tesetaxel 61 IMP# 61 administered subcutaneously 61 Romidepsin 61 LY# [003] 61 Taxotere chemotherapy 61 treatment naive genotype 61 potent antitumor activity 61 sorafenib tablets 61 Phase IIIb clinical 61 relapsing remitting MS RRMS 61 Exherin TM 61 invasive candidiasis 61 cathepsin K inhibitor 61 prostanoid 61 IRX 2 61 Cardiotoxicity 61 randomized multicenter trial 61 Elocalcitol 61 DNA intercalator 61 PhG alpha 1 61 evaluating satraplatin 61 NO# [002] 61 arsenic trioxide injection 61 IMGN# 61 mTOR inhibition 61 Oral NKTR 61 Cotara 61 potentially hepatotoxic 61 immunomodulatory therapy 61 Natalizumab 61 Cytoxan 61 PREZISTA r 61 cinacalcet 61 antimetabolite 61 ABSORB trial 61 prasugrel Effient 61 phase IIb III 61 beta2 agonist 61 NPM1 61 Randomized Phase 61 LHRH receptor positive 61 antitumor efficacy 61 quinolone 61 reslizumab 61 radiolabeled monoclonal antibody 61 EGFR HER2 61 APOPTONE 61 rhIGFBP 3 61 selective kinase inhibitor 61 antiproliferative effects 61 CEQ# 61 Phase 1b clinical 61 nucleotide analogs 61 intravenous dosing 61 PS# [001] 61 intravascular hemolysis 61 Arikace 61 darunavir ritonavir 61 Pegasys ® 61 HIF PH inhibitors 61 abacavir lamivudine 61 azacitidine 61 nanopharmaceutical 61 Alzhemed TM 61 echinocandin 61 indolent NHL 61 verteporfin 61 octreotide 61 DFMO 61 baminercept 61 eTag assays 61 endothelin receptor 61 GV# [001] 61 Ophena 61 thrombopoietin 61 oral talactoferrin 61 pharmacodynamic biomarkers 61 signal transduction inhibitor 61 refractory cutaneous T 61 Copegus ribavirin 61 prospectively defined 61 TPI ASM8 61 KRAS mutations occur 61 cangrelor 61 docetaxel Taxotere 61 pretargeting 61 ORMD 61 thetreatment 61 novel VDA molecule 61 Kinoid 61 mRCC 61 AZT zidovudine Retrovir 61 EGFR TKIs 61 tolvaptan 61 FDG uptake 61 miconazole Lauriad ® 61 TREDAPTIVE 61 Bayer HealthCare Onyx Pharmaceuticals 61 IIa trial 61 retapamulin 61 LB# [003] 61 Peg IFN 61 Denufosol 61 Dalbavancin 61 GW# [003] 61 EDEMA3 61 LymphoStat B belimumab 61 bronchodilatory 61 novel anticancer 61 XOMA 3AB 61 peg interferon 61 human microdosing 61 CCR5 mAb 61 ChronVac C R 61 HBeAg 61 androgen receptor antagonist 61 ALTROPANE 61 rhIL 7 61 JAK2 inhibitor 61 multitargeted 61 Prodarsan ® 61 sufentanil 61 MAb 61 Prostate AdenoCarcinoma Treatment 61 desvenlafaxine succinate 61 hyaluronidase enzyme 61 lytic 61 non nucleoside HCV 61 unique alkylating agent 61 immunomodulation 61 HGS ETR1 mapatumumab 61 LEP ETU 61 antibody MAb 61 RE LY 61 VITAL Trial 61 factor Xa 61 LymphoStat B TM 61 ToGA 61 relapsed refractory multiple myeloma 61 fluticasone furoate 61 seliciclib 61 SPIRIT FIRST 61 CD# antibody [001] 61 Phase III randomized controlled 61 DermaVir 61 ACTEMRA TM 61 PI3K inhibitors 61 pyridostigmine 61 doxorubicin cyclophosphamide 61 lomitapide 61 sustained virological response 61 superficial bladder cancer 61 deforolimus 61 Phase Ib 61 ^ sup #m 61 UGT#A# 61 irinotecan chemotherapy 61 Imprime PGG 61 BMS # 61 Ziprasidone 61 Anticalins ® 61 Nitazoxanide 61 PEGylated 61 immunomodulatory properties 61 dasatinib Sprycel ® 61 diagnostic biomarker 61 Orazol 61 stated Michelle Berrey 61 ATL# [001] 61 ulimorelin 61 ProSavin 61 Dose escalation 61 certolizumab 61 Angiolix 61 RGB # 61 Zolinza 61 uricase 61 systemically administered 61 Resten NG 61 lapatinib Tykerb 61 Alfacell proprietary ribonuclease 61 5 fluorouracil leucovorin 61 dose escalation 61 BENICAR HCT 61 PEGPH# 61 TRISENOX ® 61 neuroregenerative 61 pegnivacogin 61 murine model 61 theranostic 61 Serdaxin ® 61 tolevamer 61 virological response 61 MetMAb 61 Solulin 61 follicular NHL 61 diabetic neuropathic pain 61 ACTOS ® 61 paclitaxel Taxol R 61 Initiate Phase 61 strontium ranelate 61 Aliskiren 61 cannabinor 61 bardoxolone 61 TELCYTA 61 teduglutide 61 Valsartan 61 PF # [001] 61 Myelodysplastic Syndrome MDS 61 Pharmacodynamic 61 Prestara 61 DLTs 61 ROCKET AF 61 tarenflurbil 61 Inhalation Solution 61 Akt inhibitor 61 novel oral anticoagulant 61 C1 INH 61 QLT# 61 Phase IIA 61 Fc gamma receptor 61 splice variants 61 lucinactant 61 nucleoside reverse transcriptase inhibitor 61 Meets Primary Endpoint 61 INCB# [003] 61 K ras mutations 61 prostate cancer PCa 61 PEGylated interferon beta 1a 61 heavily pretreated 61 HIV RNA 61 Seliciclib 61 AVADO 61 KRN# 61 evaluating Xcytrin 61 REG1 61 pharmacodynamic endpoints 60 plasma uric acid 60 dosing cohorts 60 Pimavanserin 60 myocardial necrosis 60 generation antisense inhibitor 60 EndoTAG 60 Pharmacokinetic parameters 60 immunotherapeutic agent 60 active comparator 60 iodixanol 60 NVA# 60 pharmacokinetic characteristics 60 Alkaline Phosphatase 60 predictive biomarker 60 Aurora kinase 60 lexidronam injection 60 NEUMUNE 60 LEXIVA r 60 isotype 60 ONCONASE 60 small molecule chemotherapeutic 60 alfa 2a 60 TRISENOX 60 cell lymphoma CTCL 60 nucleotide analogue 60 urate lowering